Tissue Regenix - senior development appointment

RNS Number : 5720N

Tissue Regenix Group PLC

01 October 2012

 



Tissue Regenix makes senior development appointment

Rob Snell appointed to lead growing development and manufacturing operations

York - 1 October 2012 - Tissue Regenix Group plc ('Tissue Regenix') the regenerative medical technology specialist has appointed Rob Snell as Development Manager to lead the key development and manufacturing operations across the group.

Rob's appointment is a key part of Tissue Regenix's strategy, following the December 2012 fundraising,  to accelerate the development of a range of products based on its patented dCELL® regenerative medicine process, which removes cells and other components from human and animal tissue allowing it to be used without anti-rejection drugs to replace worn out or diseased body parts.

Rob's primary role will be to lead the project teams currently focussed on a range of different products to ensure their timely delivery to the market.

Rob Snell joins Tissue Regenix from medical devices company Ranier Technology where he worked as Technical Director, responsible for its Cadisc^TM spinal implants. Rob has spent almost 20 years in technical development within the medical industry, developing devices in the fields of orthopaedics, cardiology, urology and thin film barrier products.

His appointment follows the recent hiring of Andrea Rausch as Business Development Manager who joined from Sorin Group to lead the global business development drive for Tissue Regenix's Cardiac products, including vascular patches and heart valves. 

Antony Odell, Managing Director of Tissue Regenix stated: "We are delighted that Rob is joining our senior team to help us lead the expanded development team as we progress the development of our pipeline of products and applications based on the dCELL® technology platform."

-ENDS-

For Further Information

Tissue Regenix Group plc:                                                           01904 435 176

Antony Odell

Ian Jefferson

Peel Hunt LLP (Nominated Adviser)                                        020 7418 8900

James Steel

Vijay Barathan

Newgate Communications

Alistair Kellie                                                                                    07557 651840

Andrew Adie                                                                                     07970 256512

Martin Greig                                                                                      07584 221513

About Tissue Regenix

Tissue Regenix, (AIM:TRX) the regenerative medical devices company , was incorporated in May 2006 to commercialise the academic research of Professor Eileen Ingham and Professor John Fisher from the University of Leeds in the field of tissue decellularisation.

 

END

 

 

NRAZMMGGLMRGZZG